ストックスクリーナーアプリを入手
21.54
3.80%
-0.85
アフターアワーズ：
21.43
-0.11
-0.51%
前日終値:
$22.39
開ける：
$21.88
24時間の取引高:
88,056
Relative Volume:
0.73
時価総額：
$238.13M
収益：
$56.54M
当期純損益:
$-30.70M
株価収益率:
-55.23
EPS:
-0.39
ネットキャッシュフロー:
$-31.05M
1週間 パフォーマンス:
-8.84%
1か月 パフォーマンス:
-13.49%
6か月 パフォーマンス:
+100.37%
1年 パフォーマンス:
+17.07%
1日の値動き範囲:
$21.04
$22.64
1週間の範囲:
$19.83
$23.50
52週間の値動き範囲:
$10.00
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
名前
Cidara Therapeutics Inc
セクター
電話
858-752-6170
住所
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.54 | 238.13M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-12 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-01-27 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-08 | 開始されました | Guggenheim | Buy |
| 2024-08-14 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 再開されました | H.C. Wainwright | Buy |
| 2021-09-22 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 開始されました | Aegis Capital | Buy |
| 2019-09-04 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-07-26 | 開始されました | Citigroup | Buy |
| 2017-04-21 | 開始されました | Raymond James | Strong Buy |
| 2017-04-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-04-11 | 再開されました | Wedbush | Outperform |
| 2017-02-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-22 | アップグレード | WBB Securities | Sell → Hold |
| 2016-12-21 | 再開されました | Leerink Partners | Outperform |
| 2016-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2016-09-23 | ダウングレード | WBB Securities | Hold → Sell |
| 2015-10-09 | アップグレード | WBB Securities | Sell → Hold |
| 2015-05-11 | 開始されました | Jefferies | Buy |
| 2015-05-11 | 開始されました | Leerink Partners | Outperform |
| 2015-05-11 | 開始されました | Needham | Buy |
| 2015-05-11 | 開始されました | Wedbush | Outperform |
| 2015-04-23 | 開始されました | WBB Securities | Sell |
すべてを表示
Cidara Therapeutics Inc (CDTX) 最新ニュース
(CDTX) Investment Analysis - news.stocktradersdaily.com
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know - Yahoo Finance
Cidara Therapeutics to Participate in World Health - GlobeNewswire
Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance
Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World
Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire
Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire
Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World
(CDTX) Long Term Investment Analysis - Stock Traders Daily
Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia
Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com Australia
Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India
Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India
Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World
Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq
Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha
Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada
FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks
HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World
Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing - TipRanks
Cidara Therapeutics Advances with Strong Financial Backing - TipRanks
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) - Defense World
Cidara Therapeutics: Q4 Earnings Snapshot - Barchart
Cidara Therapeutics reports wider Q4 loss, shares dip - Investing.com
Cidara Therapeutics reports wider Q4 loss, shares dip By Investing.com - Investing.com South Africa
Cidara Therapeutics: Q4 Earnings Snapshot -March 06, 2025 at 05:03 pm EST - Marketscreener.com
Cidara Therapeutics Completes Enrollment in Phase 2b NAVIGATE Trial and Secures $105 Million in Financing - Nasdaq
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Cidara's $196M War Chest and 5,000-Patient Trial Transform Flu Prevention? - StockTitan
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
(CDTX) Trading Signals - Stock Traders Daily
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Infectious disease index recovers from -25% low, ends 2024 down 6.28% - BioWorld Online
Cidara Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective February 24, 2025 - Marketscreener.com
Cidara Therapeutics Inc (CDTX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):